References

1. Gan L, Yang Y, Li Q, et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10.
2. Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22(2):12-34.
3. Weikert S, Christoph F, Köllermann J, et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med. 2005;16(2):349-353.
4. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 2003;100:11606-11611.
5. Böhm J, Muenzner JK, Caliskan A, et al. Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells. J Cancer Res Clin Oncol. 2019; 145:2227-2240.
6. Gu Y, Zhang J, Guan H. Expression of EZH2 in endometrial carcinoma and its effects on proliferation and invasion of endometrial carcinoma cells. Oncol Lett. 2017;14(6):7191-7196.
7. Frankel AE, Liu X, Minna JD. Developing EZH2-Targeted therapy for lung cancer. Cancer Discov. 2016;6(9):949-952.
8. Bödör C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165-3168.
9. Lue JK, Prabhu SA, Liu Y, et al. Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas. Clin Cancer Res. 2019;25(17):5271-5283.
10. Jones BA, Varambally S, Arend RC. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. Mol Cancer Ther. 2018;17(3):591-602.
11. Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell. 2013;4(5):331-341.
12. Wu X, Scott H, Carlsson SV, et al. Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate. 2019;79(10):1079-1089.
13. Zhang D, Xue Y, Yang X, et al. 118 EZH2 is overexpressed and contributes to apoptotic-resistance and metastasis in renal cell carcinoma. J Urol. 2011;185(Suppl):e50.

Drug Table References:

1. Epizyme, Inc. TAZVERIK (tazemetostat) tablets, for oral use [package insert]. Revised July 2020. www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/sites/9/2022/11/03075215/TAZ-US-000213_TAZVERIK-US-PI-1.pdf. Accessed November 30, 2022.
2. Our Pipeline: Potential Breakthroughs in the Making. Pfizer Inc. Accessed November 30, 2022. www.pfizer.com/science/drug-product-pipeline.